Table 5. NK-92 dosing and clinical outcomes.
| Patient # | Dose level | Number of cycles | Number of cells administered (Total ×109) |
Response | Alive |
|---|---|---|---|---|---|
| 01 | 1 | 1 | 6 | MR | No |
| 02 | 1 | 3 | 15.93 | PD | No |
| 03 | 1 | 5 | 30 | CR* | Yes |
| 04 | 2 | 1 | 14.49 | PD | No |
| 05 | 2 | 3 | 51.84 | CI** | No |
| 06 | 2 | 6 | 109 | MR | No |
| 07 | 3 | 5 | 150 | PD | No |
| 08 | 3 | 1 | 27.42 | PD | No |
| 9 | 3 | 3 | 77.68 | PD | No |
| 10 | 1 | 6 | 24.67 | PD | Yes |
| 11 | 1 | 6 | 25.11 | CR*** | Yes |
| 12 | 1 | 5 | 23 | PD | Yes |
*Patient 03 had increase in lymphadenopathy/splenomegaly interpreted as progression, with subsequent resolution to CR × 10 years after NK-92 therapy.
**Patient 05 had clinical improvement after 2 cycles of NK-92.
**Patient 11 achieved complete response after NK-92 therapy and also received concomitant Lenalidomide-Dexamethasone therapy during and after the infusions.
Abbreviations: PD: progressive disease; CR: Complete response, MR: minor response, CI: Clinical improvement in symptoms.